by | Nov 12, 2024 | Lupus Foundation of America, News & Events
In a new study, researchers discovered a potential new genebiomarker, ELF1, a protein coding gene, that can be used to diagnose and evaluate people with systemic lupus erythematosus (SLE). Researchers analyzed integrated genetic data from Genome-Wide Association...
by | Nov 12, 2024 | Lupus Foundation of America, News & Events
A range of medications are available to help treat lupus nephritis (LN), each offering a specific role in managing the condition. In a recent study, researchers evaluated published research on LN, focusing on treatment trends. This literature review suggests treatment...
by | Nov 5, 2024 | Lupus Foundation of America, News & Events
Vitamin D affects how your immune system works, and plays a role in controlling certain types of inflammation, including the type that leads to autoimmune diseases. It’s common for people with lupus to have low levels of vitamin D. In a recent study, researchers...
by | Nov 4, 2024 | Lupus Foundation of America, News & Events
Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a phase 2 study for people with systemic lupus erythematosus (SLE) in 2025. The first drug of its kind to advance into clinical development,...
by | Nov 1, 2024 | Lupus Foundation of America
Each year, Medicare beneficiaries are given the opportunity to select a new plan for the upcoming year during the Open Enrollment Period. This year, Open Enrollment begins on October 15 and will run until December 7, 2024 – for most people, this will be the only...
by | Oct 31, 2024 | Lupus Foundation of America, News & Events
In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy CMG1A46 from Chimagen Biosciences, a privately-held biotechnology company based in China. Per the terms of the deal, GSK will pay Chimagen $300...
